



PRESS RELEASE

Heidelberg, September 14th, 2017

What probiotics promise and can achieve

Prof. Dr. Christine Lang at the Microbiome Congress in Heidelberg

The demand for probiotics as part of a regimen of dietary supplements, for example, is growing, but in order to understand the way they work, consumers must take a close look. This is pointed out by Prof. Dr. Christine Lang. She is investigating the positive effect of bacteria on, inter alia, the development of new substances that are intended to maintain skin and intestinal health. At the Microbiome Congress in Heidelberg on September 16th she speaks about current findings in probiotic and microbiome research.

“For a healthy balance of the numerous different intestinal bacteria, it can be helpful to take probiotic preparations,” explains Prof. Lang in the lead-up to the event. She said it is important to consider that they contain specific and well-researched probiotic strains and there are clinical studies that prove their positive effect.

Since the composition of the intestinal flora can differ from person to person, there are already promising approaches to determine the specific composition of one’s own intestinal flora or intestinal microbotics and to adapt preparations and therapies accordingly. “It is important that we know even more about it and that we are able to apply this knowledge when using probiotics.”

Organobalance, the research company led by Christine Lang, has for example identified the special strain *Lactobacillus reuteri* DSM17648 from its own collection of several thousand bacteria — based on its specific ability to bind to the stomach bacteria *Helicobacter pylori*. “Such an intensive screening process is optimal,” comments Prof. Lang, “but also time-consuming. The research has come a very long way in the past years, but we still do not know the majority of the microbiome,” concludes Prof. Lang.

Doctors, nonmedical practitioners, and companies are expected at the Congress titled “Influencing the Microbiome as a Therapeutic Option” in the Heidelberg City Hall. More information is available at <https://www.symbiopharm.de/de/fachbereich/mikrobiom-kongress.html>.



About Organobalance:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best-known products is Pylopass™, a natural lactobacillus agent able to bind Helicobacter pylori, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. Christine Lang, the company's Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and has received several business awards. She also chairs the German Bioeconomy Council. Since September 2016, Organobalance has become a part of the Danish company Novozymes A/S.

For further information:

ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Fon +49 (0) 30 46307 200
Fax +49 (0) 30 46307 210
www.organobalance.com